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Moving beyond size and phosphatidylserine exposure: evidence for a diversity
of apoptotic cell-derived extracellular vesicles in vitro
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Christopher D. Gregoryb, Dilara C. Ozkocaka, Stephanie F. Ruttera, Sarah Carusoa, Jascinta P. Santavanonda,
Stephanie Paonea, Bo Shia, Amy L. Hodgea, Mark D. Huletta, Jenny D. Y. Chowa, Thanh Kha Phana
and Amy A. Baxtera
aDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia; bMRC Centre
for inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
ABSTRACT
Apoptosis is a form of programmed cell death that occurs throughout life as part of normal
development as well as pathologic processes including chronic inflammation and infection.
Although the death of a cell is often considered as the only biological outcome of a cell
committed to apoptosis, it is becoming increasingly clear that the dying cell can actively
communicate with other cells via soluble factors as well as membrane-bound extracellular
vesicles (EVs) to regulate processes including cell clearance, immunity and tissue repair.
Compared to EVs generated from viable cells such as exosomes and microvesicles, apoptotic cell-
derived EVs (ApoEVs) are less well defined and the basic criteria for ApoEV characterization have
not been established in the field. In this study, we will examine the current understanding of
ApoEVs, in particular, the ApoEV subtype called apoptotic bodies (ApoBDs). We described that
a subset of ApoBDs can be larger than 5 μm and smaller than 1 μm based on flow cytometry and
live time-lapse microscopy analysis, respectively. We also described that a subset of ApoBDs can
expose a relatively low level of phosphatidylserine on its surface based on annexin A5 staining.
Furthermore, we characterized the presence of caspase-cleaved proteins (in particular plasma
membrane-associated or cytoplasmic proteins) in samples enriched in ApoBDs. Lastly, using
a combination of biochemical-, live imaging- and flow cytometry-based approaches, we char-
acterized the progressive lysis of ApoBDs. Taken together, these results extended our under-
standing of ApoBDs.
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Major EV subtypes including exosomes and microvesi-
cles are recognized as key regulators of intercellular com-
munication and could participate in processes such as
inflammation, immune responses, coagulation, tumori-
genesis and host–microbe interactions [1–6].
Furthermore, a number of studies have proposed the
use of EV subtypes and EV-associated contents as bio-
markers for pathologic conditions including cardiovascu-
lar, autoimmune and neurodegenerative diseases [1–6].
Therefore, the field has made a significant effort to better
define EVs generated from viable cells, and establish
extensive guidelines for studying them [7–11]. In con-
trast, EVs derived from apoptotic cells (denoted as
ApoEVs) are generally less well defined, with most stu-
dies in the field of EVs and cell death systematically
removing them from analysis rather than performing
detailed characterization. It has been estimated that up
to 100–150 billion cells will die via apoptosis daily in the
human body to maintain homeostasis [12,13], and the
frequency of apoptosis is higher in disease settings includ-
ing infection [14,15], as well as medical interventions like
in chemo-/radio-therapy [16,17]. Thus, ApoEVs are
a major subtype of EVs from apoptotic cells that could
be released under physiologically relevant settings and
their properties need to be better defined.
ApoEVs is a broad term that can be used to describe
EVs generated from apoptotic cells [18]. Larger
ApoEVs are categorized as ApoBDs (generally consid-
ered as 1–5 μm in diameter based on light and electron
microscopy studies) [3,19–22], whereas smaller
ApoEVs are described as apoptotic microvesicles
(ApoMVs, generally considered as 0.1–1 μm in dia-
meter) based on their size similarities with microvesi-
cles generated from viable cells [1,3]. Recently,
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exosome-like vesicles (<150 nm) that are released dur-
ing the progression of apoptosis were also character-
ized [23]. It is worth noting that different subtypes of
ApoEVs may exhibit different functional properties.
For example, ApoBDs but not ApoMVs generated
from stress-activated apoptotic human endothelial
cells were able to drive sterile inflammation through
the trafficking of IL-1α [24]. Thus, it is important to
distinguish different ApoEV subtypes. In this study, we
will focus on ApoBDs and how we could better define
this ApoEV subtype. It should be noted that different
ApoEV subtypes may overlap in size and whether size
is the best criterion to distinguish different ApoEV
subtypes is debatable. Nevertheless, since there is cur-
rently no single parameter to clearly distinguish
ApoBDs from other ApoEV subtypes, we will continue
to use the size-based definition as described above in
this study. It is worth noting that ApoBDs are also
described in the literature (e.g. in primary research
[25–29] and review articles [30–32]) as EVs that are
“0.05–5 μm” or “<1.2 μm” in diameter, and we will not
adopt this description as it does not account for differ-
ent ApoEV subtypes.
Based on the size of ApoBDs, they can be easily
visualized by standard light and electron microscopy
[33–38], and quantified in a semi high-throughput
manner by flow cytometry [39–42], image-based
flow cytometry [36] and tunable resistive pulse sen-
sing [43,44]. In addition to simply detecting vesicles
that are 1–5 μm in diameter to conclude the presence
of ApoBDs in a sample, hallmarks of apoptosis can
also be monitored to provide further evidence that
ApoBDs are indeed formed under specific experi-
mental conditions [24,36,40,45–47]. Hallmarks of
apoptosis (e.g. caspase activation, DNA fragmenta-
tion) are well defined [33,48–50], and more recently,
morphological steps of apoptotic cell disassembly (the
process of ApoBD formation) are beginning to be
characterized in detail [36,40,45,51,52]. Since
ApoBDs can only be generated during apoptosis
and after distinct morphological steps of apoptotic
cell disassembly have occurred, a number of studies
have validated these events in addition to detecting
the presence of vesicles that are between 1 and 5 μm
in diameter [24,36,42,43,45,51,53,54]. Thus, for
in vitro studies, it is important to monitor the level
of apoptosis from cells that have generated ApoBDs.
Likewise, monitoring the morphological steps of
apoptotic cell disassembly, namely plasma membrane
blebbing, thin membrane protrusion formation (e.g.
apoptopodia) and the generation of distinct ApoBDs
(i.e. not blebs that are still on the surface of the
apoptotic cell) will provide clear evidence that
ApoBDs are indeed generated from cells undergoing
apoptosis. For tissue samples, ApoBDs can also be
readily observed by electron microscopy along with
other hallmarks of apoptosis such as nuclear conden-
sation and organelle fragmentation [33,48,55], thus
further confirming the identification of ApoBDs.
Although ApoBDs can be easily visualized as they
are one of the largest types of extracellular vesicles,
many properties of ApoBDs are yet to be fully char-
acterized. To better understand the nature of
ApoBDs, certain properties of ApoBDs such as size,
markers and membrane permeability will be exam-
ined and/or discussed in this study to help establish
suitable criteria for studies of ApoBDs. It should be
noted that the purpose of this study is not to propose
strict rules to define ApoBDs but to highlight para-
meters investigators should consider when studying
ApoBDs.
Materials and methods
Cell lines and tissue culture
Human LIM1215 colorectal epithelial cells were gifted
from Dr Suresh Mathivanan (La Trobe University,
Australia), human THP-1 monocytic and Jurkat
T (clone E6-1) cells were obtained from ATCC (TIB-
202 and TIB-152, respectively). PANX1−/− GFP+
mCherry+ (clonal) Jurkat T cells were generated by
a CRISPR/Cas9-based approach [56]. All cell lines
were cultured at 37°C in a humidified atmosphere
with 5% CO2, in RPMI 1640 medium (Life
Technologies) supplemented with 5% fetal bovine
serum (FBS) (Gibco), penicillin (50 U/ml) and strepto-
mycin (50 μg/ml) (Thermo Fisher Scientific), and
MycoZap (0.2% v/v) (Lonza).
Apoptosis induction
Unless stated otherwise, cells for apoptosis induction
were prepared in serum-free RPMI supplemented with
1% bovine serum albumin (BSA). Apoptosis was
induced via UV irradiation (150 mJ/cm2) using
a Stratalinker UV Crosslinker 1800 (Agilent
Technologies) followed by incubation at 37°C under
a humidified atmosphere with 5% CO2 for indicated
times. The formation of ApoBDs by cells undergoing
apoptosis, including the morphological steps of apop-
totic cell disassembly, following UV irradiation was
characterized extensively in previous studies [36,45]
and level of apoptosis and ApoBD formation validated
by flow cytometry as described below. It should be
noted that ApoBD-like vesicles were not detected in
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1% BSA/RPMI or 5% FBS/RPMI (Supplementary
Figure 1, Supplementary Video 1, 2 and 3).
Preparation of ApoBD depleted and ApoBD
enriched samples
ApoBD depleted and ApoBD enriched samples were
prepared via a differential centrifugation approach as
described previously [57]. Briefly, THP-1 and Jurkat
T cells were collected 3–4 h post apoptosis induction
and pelleted by centrifugation (Allegra® X-15R
Centrifuge, SX4750/SX4750A, Beckman Coulter) at
300 g for 10 min to pellet cells (viable, apoptotic,
necrotic cells) and some large ApoBDs (i.e. ApoBD
depleted sample). The supernatant was then collected
and centrifugation at 3,000 g for 20 min was performed
to pellet EVs including ApoBDs (ApoBD enriched
samples). It should be noted that no degradative
enzymes or additional mechanical force were applied
(other than the described procedure such as transfer-
ring the apoptotic samples between tubes for differen-
tial centrifugation and resuspending cell/vesicle pellets
for flow cytometry and immunoblot analysis) to collect
the samples.
Preparation of 3K, 16K and 100K samples
generated from apoptotic cells
Jurkat T cells were prepared in serum-free RPMI supple-
mented with 1x Insulin-Transferrin-Selenium (ITS)
(Thermo Fisher Scientific). Apoptosis was induced via
UV irradiation as described above, followed by incubation
at 37°C under a humidified atmosphere with 5% CO2 for 4
h (control samples were incubated under the same condi-
tions in the absence of UV irradiation). Samples were first
centrifuged at 300 g for 10 min and cell pellets were col-
lected. Sequential centrifugation was then performed on
cell-free supernatants: Samples were centrifuged at 3,000
g for 20 min. Pellets were then collected (“3k”) and super-
natantswere centrifuged at 16,000 g for 40min. Pelletswere
then collected (“16k”) and supernatantswere centrifuged at
100,000 g followed by collection of pellets (“100k”). All
pellets were gently resuspended by pipetting and washed
in 1 x PBS followed by a second centrifugation step.
Centrifugation at 300 and 3,000 g was performed on an
Allegra® X-15R Centrifuge and Eppendorf 5415
R centrifuge (Eppendorf). Centrifugation at 16,000 g was
performed on an OptimaTM L-100 XP Ultracentrifuge,
SW28 (Beckman Coulter) and Eppendorf 5415
R centrifuge. Centrifugation at 100,000 g was performed
on an OptimaTM L-100 XP Ultracentrifuge and an
OptimaTM Max-MP Ultracentrifuge, TLA55 (Beckman
Coulter). Samples were stored at −80°C until required.
Flow cytometry
The level of apoptosis and ApoBD formation was
quantified by flow cytometry as per previous studies
[39]. Briefly, samples were incubated in a final concen-
tration of 1× annexin A5 (A5) binding buffer (Thermo
Fisher Scientific), 1 in 200 A5-FITC (Thermo Fisher
Scientific) and 1 μM TO-PRO-3 (Thermo Fisher
Scientific) for 10 min at room temperature in the
dark. Samples were then kept on ice and in the dark
until flow cytometry analysis using the BD FACSCanto
II (FSC resolution of 1 μm, BD Biosciences). Notably,
for adherent cells like human LIM1215 colorectal
epithelial cells, only apoptotic cells and ApoBDs that
are detached from the culture plates during the pro-
gression of apoptosis were analysed and no degradative
enzymes or additional mechanical force were applied.
For size determination of ApoBDs, polystyrene micro-
spheres of 4 μm, 6 μm, 10 μm and 15 μm (Thermo
Fisher Scientific) were prepared as per manufacturer’s
instructions and quantified by flow cytometery along-
side ApoBDs. Resultant data were analysed using
FlowJo software version 8.8.10 (Tree Star) and electro-
nic gating strategy was applied as described previously
[39]. It should be noted that the FACSCanto II flow
cytometer used in this study was not calibrated for
small particle analysis. Nevertheless, it is possible that
large MV-like vesicles were detected and included in
the flow cytometery analysis.
Confocal microscopy
Samples in 1% BSA/1× A5 binding buffer/RPMI were
stained with A5-FITC or A5-APC and seeded into wells
of a Lab-Tek II 8-well chamber slide (Nunc). Live micro-
scopy was performed on either a Zeiss Spinning disk,
LSM 780 or LSM 800 confocal microscope (Zeiss) at 37°
C in a humidified atmosphere containing 5% CO2, and
using a 63× oil immersion objective. For experiments
involving phosphatidylserine (PtdSer) detection on
ApoBDs, images were collected over approximately 1
h. For experiments in which non-UV-irradiated cells
and ApoBD stability were monitored, time-lapse micro-
scopy was performed over 4 to 6 h. All images were
analysed using ZEN Lite 2.3 program (Zeiss).
Immunoblotting
Immunoblotting of cell and ApoBD samples: Cell and
ApoBD samples were collected and lysed in lysis buffer
(20 mM HEPES pH 7.4, 1%, IGEPAL® CA-630, 10%
glycerol, 1% Triton X-100, 150 mM NaCl, 50 mM NaF,
protease inhibitor cocktail tablet (Roche)). Next, 20–40
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µg of protein was separated on a 12% SDS-PAGE gel and
proteins were transferred to a nitrocellulose membrane.
Immunoblotting was performed with the following anti-
bodies: PANX1 (Clone D9M1C, Cell Signaling
Technology), ROCK1 (Clone C8F7, Cell Signaling
Technology), PARP1 (Clone 46D11, Cell Signaling
Technology) and β-actin (Clone AC-74, Sigma-Aldrich).
Immunoblotting of EVs isolated via differential
centrifugation: Cell pellets were lysed in Cytobuster
Protein Extraction Reagent (Merck Millipore) to
acquire whole cell lysates (WCL). WCL, 3k, 16k and
100k EV pellets were then treated with LDS loading
dye and DTT followed by heating at 90°C for 5 min.
5 μl of protein were then separated on a 12% SDS-
PAGE gel. Gels were stained with SYPRO® Ruby
Protein Gel Stain (Thermo Fisher Scientific) accord-
ing to manufacturer’s instructions. Protein quantifi-
cation by densitometry was then performed using
ImageJ software. Next, 20–40 µg of protein was sepa-
rated on a 12% SDS-PAGE gel (omitting DTT and
sample heating steps for gels run under non-
denaturing conditions) and proteins were transferred
to PVDF membranes. Immunoblotting was per-
formed with the following antibodies: Alix (Clone
3A9, Cell Signaling Technology), CD81 (Clone M38,
Thermo Fisher Scientific) (under non-denaturing
conditions) and BiP/GRP78 (Clone 40/BiP, BD
Biosciences).
LDH release assay
The release of LDH by isolated ApoBDs was deter-
mined using the LDH Cytotoxicity Assay Kit II
(Abcam). Briefly, following apoptosis induction,
ApoBDs were isolated via differential centrifugation
as per above. Isolated ApoBDs were then incubated at
37°C in a humidified atmosphere with 5% CO2 for 0, 3
or 6 h. Total lysis was determined by treatment of
ApoBDs with LDH kit lysis buffer for 30 sec. All
samples were then pelleted by centrifugation at 3,000
g for 5 min, with supernatant collected and analysed as
per the manufacturer’s instructions. Absorbance read-
ings of LDH reaction products were measured at 450




The diameter of an EV has been an important criter-
ion to distinguish the major subtypes of EVs includ-
ing exosomes, microvesicles, ApoBDs and oncosomes
[1,2,19,58]. Although the general conception of
ApoBDs being 1–5 μm in diameter is a relatively
good guideline, it is also clear that this description
of ApoBDs needs to be revised. In particular, the size
of ApoBDs should be cell type dependent due to
differences in cell size and the mechanism of
ApoBD formation (Table 1). To this end, we mon-
itored ApoBDs generated from human Jurkat T cells,
LIM1215 colon carcinoma cells and THP-1 monocy-
tic cells and found that a subset of ApoBDs derived
from these human cell lines was as large as 8–10 μm
[39] (Figure 1(a,b)), which are larger than some
mouse haematopoietic cells [36,59–61]. Thus, it may
not be appropriate to set the upper limit of ApoBDs
as 5 μm in diameter for all cell types. Furthermore,
ApoBDs derived from human monocytes are gener-
ated predominately through the fragmentation of thin
“beads-on-a-string” membrane protrusions called
beaded apoptopodia [45,62]. We monitored the for-
mation of beaded apoptopodia on apoptotic THP-1
monocytic cells and observed that many of the con-
necting “beads” of the beaded apoptopodia had
a diameter of less than 1 μm (Figure 1(c)), suggesting
the fragmentation of these membrane protrusions
could generate ApoBDs smaller than 1 μm. Thus,
setting the lower limit of ApoBDs as 1 μm in dia-
meter may not be suitable for cells that undergo
apoptotic cell disassembly via a beaded apoptopodia-
dependent mechanism.
Positive markers of ApoBDs
Defining specific markers that could help distinguish
different EV subtypes is a major goal in the field [7,8].
Depending on the nature of these markers (i.e. surface
exposed or intracellular), they could be used to detect
and isolate EV of interest or validate the EV subtypes
present in a sample [7,8]. To date, markers associated
with ApoBDs include PtdSer (a phospholipid exposed
on the surface of apoptotic cells and ApoBDs to pro-
mote recognition and clearance by phagocytes [13]),
nuclear proteins and DNA [1–3], as well as calreticulin
[28,62], calnexin [63] and BiP/GRP78 [64]. It should be
noted that these markers are not necessarily exclusive
on/in ApoBDs compared to other EV subtypes [2,28].
In this section, we will evaluate the properties of some
of these markers on/in ApoBDs.
Firstly, protein characterization by immunoblotting
was performed on Jurkat T cells-derived EVs isolated
via 3k, 16k and 100k differential centrifugation in order
to compare distribution of typical EV markers in 16k
and 100k samples with 3k samples (i.e. samples con-
taining ApoBDs). Endoplasmic reticulum resident
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protein BiP/GRP78 was detected in 3k but not 16k or
100k fractions, whereas tetraspanin membrane protein
CD81 and ESCRT-associated protein Alix were most
abundant in 16k and 100k fractions (Supplementary
Figure 2).
The ability of apoptotic cells to expose PtdSer via
a caspase-dependent mechanism is a relatively well-
described process, in particular through the activation of
the scramblase Xkr8 [65] and inhibition of flippases
ATP11A and ATP11C [66]. Since the formation of
ApoBDs is a somewhat late event during the progression
of apoptosis, at a stage that PtdSer is already exposed on the
dying cell, it is not surprising that PtdSer can be found on
the surface of ApoBDs [36,39]. Despite the fact that PtdSer
can also be detected on smaller EVs like [2,67–69], PtdSer is
often used as a positive marker for ApoBDs [39]. Notably,
when we monitored the exposure of PtdSer on ApoBDs
generated from THP-1 and LIM1215 cells treated with UV
to induce apoptosis, ApoBDs were found to be either
PtdSerIntermediate or PtdSerLow based on A5 (a PtdSer-
binding protein) staining as monitored by confocal micro-
scopy (Figure 2(a,b)), indicating PtdSer exposure alone
may not be a suitable marker to either include or exclude
a certain vesicle population to be classified as ApoBDs. It
should be noted that it is possible for PtdSerLow ApoBD-
like vesicles to be released from non-apoptotic cells. To
address this, we performed live time-lapse microscopy and
did not observe ApoBD-like vesicles being released from
viable cells (cells that exhibited no apoptotic morphologies
like cell detachment, cell rounding, membrane blebbing
and thin membrane protrusion formation)
(Supplementary Video 4 and 5).
Proteolytic cleavage of cellular proteins by execu-
tioner caspases like caspase 3 and 7 can facilitate the
demolition, disassembly and clearance of apoptotic cells
[13,19,70]. Thus, it is logical to assume that certain
caspase-cleaved proteins can be detected in ApoBDs.
To test this, we monitored the expression of well-
characterized caspases 3 and 7 substrates (Figure 3(a))
including PANX1 (located at the plasma membrane)
[71], ROCK1 (located in the cytosol) [46,72] and
PARP1 (located in the nucleus) [73] in ApoBD depleted
and ApoBD enriched samples generated from UV-
irradiated THP-1 monocytic cells (Figure 3(b),
Table 1. Current and proposed criteria to define ApoBDs.
Proposed
Current
Criteria Criteria Rationale / discussion
● Detection: Visualization of ApoBDs by light
microscopy or electron microscopy [33–38].
Quantification of ApoBDs by flow cytometry
[39–42].
● For in vitro studies, visualization of ApoBD for-
mation (i.e. morphological steps of apoptotic
cell disassembly) by live time-lapse microscopy.
● Visualization of ApoBDs by electron microscopy
only when appropriate.
● Monitor the level of apoptosis.
● For both microscopy and flow cytometry
approaches to detect ApoBDs, criteria below
(size, markers and other properties) should be
considered.
● Provides evidence that ApoBDs are indeed gen-
erated from cells undergoing apoptosis.
● Electron microscopy analysis is suitable to monitor
ApoBDs in tissue samples [33,48,55], however,
additional sample processing steps may alter
ApoBD properties.
● Provides evidence that apoptosis did occur as this
is the prerequisite for ApoBD formation.
● Provides evidence that the vesicles observed are
indeed ApoBDs and not other types of extracel-
lular vesicles.
● Size: 1–5 μm in diameter [3,19–22,33–38]. ● The lower and upper limit of ApoBD diameter
should be cell type dependent.
● The size of ApoBDs will vary between cell types,
likely due to differences in cell size and the
mechanism of ApoBD formation.
● Markers: PtdSer exposure [39,53], contains
nuclear proteins and DNA [1–3,24,38,81,82],
enrichment in calreticulin [28,62].
● ApoBDs can be PtdSerIntermediate or
PtdSerLow.
● Cell type-specific markers are retained on
ApoBDs [57].
● ApoBDs can be with or without DNA/nuclear
proteins [45,53].
● For immunoblot analysis of purified ApoBDs,
a number of caspase 3/7-cleaved plasma mem-
brane and cytoplasmic proteins should be
monitored.
● PtdSer exposure on ApoBDs is a spectrum.
● Cell type-specific markers are retained on ApoBDs
but at a markedly reduced level compared to
apoptotic and viable cells [57].
● Whether DNA and nuclear proteins are distributed
into ApoBDs is cell type dependent (likely due to
differences in the mechanism of ApoBD forma-
tion) and not all ApoBDs contain these nuclear
materials [45,53].
● Although caspases could be active under non-
apoptotic conditions, monitoring proteins that are
cleaved by caspase 3/7 during apoptosis in pur-
ified ApoBDs provides additional evidence that
the purified sample contain ApoBDs. It should be
noted that determining the level of calreticulin
will further validate the presence of ApoBDs
[28,62].
● Other properties: Lysed [67]. ● ApoBDs can be both intact and lysed (i.e.
membrane permeabilized, leading to leakage of
luminal material).
● ApoBDs generated under in vitro conditions will
become permeabilized over time.
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Supplementary Figure 3 for electronic gating strategy for
analysis of cells and ApoBDs). It should be noted that
the formation of ApoBDs by THP-1 cells occurs via
a beaded apoptopodia-dependent mechanism [45]
(Figure 1(a)). As expected, caspase-cleaved PANX1
and ROCK1 were readily detected in the ApoBD
enriched sample (Figure 3(c,d)). Since nuclear proteins
are not distributed into ApoBDs generated from THP-1
cells [45], PARP1 and caspase-cleaved PARP1 were not
detected in the ApoBD enriched sample (Figure 3(c)).
Although caspases like caspase 3 can be activated in
certain non-apoptotic settings [74], monitoring the pre-
sence of caspase-cleaved proteins can provide additional
evidence to determine whether ApoEVs are present in
the sample.
Additional properties of ApoBDs
If an apoptotic cell is not removed by a phagocyte in
a timely manner, the cell will progress to secondary
necrosis following plasma membrane permeabilization
[75]. Loss of plasma membrane integrity can lead to
the release of intracellular contents that could promote
unwanted inflammation as well as autoimmunity [75].
Thus, whether apoptotic cells and ApoBDs can main-
tain an intact membrane has significant functional
Figure 1. Monitoring the size distribution of ApoBDs. (a) Histogram plots of 4 μm, 6 μm, 10 μm and 15 μm polystyrene
microspheres, monitored in forward scatter (FSC) by flow cytometry. (b) A5Intermediate/High apoptotic bodies (ApoBDs) and apoptotic
cells generated from THP-1 and LIM1215 cells 4 h post-UV irradiation. Events were distributed into size ranges (μm) of <4, 4–6,
6–10, 10–15 and >15 based on bisector tool analysis of polystyrene microspheres in (a), using FlowJo software. Data are
representative of two independent experiments. (c) Live differential inference contrast (DIC) microscopy image of a THP-1 cells
undergo apoptotic cell disassembly. THP-1 cells were induced to undergo apoptosis by UV irradiation and generate ApoBDs
predominately via the fragmentation of beaded apoptopodia. Scale bar, 5 or 10 μm as indicated. Data are representative of at least
three independent experiments.
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implications. Surprisingly, ApoBDs have been
described in the field of EVs as lysed vesicles [67]
(interpreted as membrane permeabilized vesicles,
which can allow transit of luminal material to the
extracellular environment). Although a significant pro-
portion of ApoBDs can undergo membrane permeabi-
lization immediately after their formation [40], the
progression of ApoBD lysis has not been fully defined.
To this end, we have established three experimental
approaches to monitor the stability of ApoBDs
(Figure 4(a)). First, ApoBDs generated from human
Jurkat T cells and THP-1 monocytic cells were isolated
using a recently described differential centrifugation
approach [57] and the purity of ApoBDs was con-
firmed by flow cytometry (Figure 4(b)). ApoBD lysis
at a population level was determined based on the
release of the cytosolic enzyme lactate dehydrogenase
(LDH, ~140 kDa) [76] from isolated ApoBDs.
Consistent between ApoBDs derived from Jurkat and
THP-1 cells, approximately 40% and 80% of ApoBDs
Figure 2. Phosphatidylserine exposure on ApoBDs is a spectrum. A5-FITC staining of phosphatidylserine (PtdSer) on ApoBDs
generated from THP-1 (a) and LIM1215 (b) cells, as determined by confocal microscopy. A selection A5Intermediate and A5Low
ApoBDs are shown. Selected ApoBDs are displayed as z-stack images to show the distribution of A5-FITC staining on ApoBDs. Scale
bar, 5 μm. Data are representative of at least three independent experiments.
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underwent lysis at 3 and 6 h post isolation, respectively
(Figure 4(c)). To visualize the membrane permeabiliza-
tion event at a single ApoBD level, live time-lapse
microscopy was performed using the PANX1−/− GFP+
mCherry+ Jurkat T cells induced to undergo apoptosis
by UV irradiation and stained with A5-APC to label
ApoBDs (Figure 4(d)). Due to the loss of PANX1, a key
negative regulator of ApoBD formation [36], these cells
can generate a large amount of ApoBDs during apop-
tosis. Loss of mCherry fluorescence signal in ApoBDs,
indicative of mCherry (~29 kDa) release into the cul-
ture supernatant, was used as a measure of ApoBD lysis
(Figure 4(d,e)). Lastly, utilizing a similar experimental
system and previously established flow cytometry-
based method to monitor ApoBD formation and con-
tents [39,53], ApoBD lysis was determined by monitor-
ing the level of GFP fluorescence signal in ApoBDs
(Figure 4(f), Supplementary Figure 4 for electronic
gating strategy for analysis of ApoBD lysis). Similar to
LDH release and time-lapse microscopy-based
approaches, ApoBDs progressively lyse over time as
determined by flow cytometry (Figure 4(f)).
Collectively, these data suggest that ApoBDs are not
simply membrane permeabilized vesicles and, approxi-
mately 50% of ApoBDs generated from T cells and
monocytes could remain intact 3–4 h post isolation/
formation under in vitro conditions.
Discussion
Unlike other types of EVs such as exosomes, micro-
vesicles and large oncosomes, ApoBDs are produced
only by apoptotic cells that have undergone the apop-
totic cell disassembly process. Therefore, it is highly
recommended that if ApoBDs are studied and/or iso-
lated under in vitro conditions, the levels of apoptosis
and/or the cell disassembly process are monitored
Figure 3. Monitoring caspase-cleaved substrates in purified ApoBDs. (a) Schematic of caspase 3/7 targeting substrates at the plasma
membrane, cytoplasm and nucleus. (b) Flow cytometry analysis of the relative levels of viable cells, apoptotic cells, ApoBDs and
necrotic cells in untreated, UV-treated, ApoBD depleted and ApoBD enriched samples (n = 3). THP-1 monocytes were used as
a model cell line. The presence of (c) PANX1 and caspase-cleaved PANX1, PARP1 and caspase-cleaved PARP1, (d) ROCK1 and
caspase-cleaved ROCK1 in untreated and apoptotic samples was determined by immunoblotting. Data are representative of at least
two independent experiments.
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(Table 1, Figure 5). It should be noted that the presence
of larger EVs in a sample (e.g. EVs that are >1 μm in
diameter) does not necessarily indicate they are
ApoBDs. To support this argument, large oncosomes
(>1 to >10 μm in diameter) [77] were found to be
distinct from ApoBDs based on the demonstration
that apoptosis was not evident in culture conditions
where large oncosomes were generated from human
DU145 prostate cancer cells [78]. Similarly, we have
also demonstrated previously that the plant defensin
NaD1 can induce primary necrosis but not apoptosis
[39,76,79]. However, Jurkat T cells treated with NaD1
resulted in the formation of EVs that resemble ApoBDs
[39]. Thus, if apoptosis was not monitored in comple-
ment to EV detection, an incorrect conclusion could
have been made. Nevertheless, it is understandable that
if ApoBDs were isolated from/detected in, for example,
in vivo or patient samples, it may not be feasible to
monitor the level of apoptosis. In these settings, mon-
itoring caspase-cleaved proteins in EV samples as sug-
gested in this study would provide complementary
evidence that the sample is likely to contain EVs gen-
erated from apoptotic cells. Furthermore, it is worth
noting that ApoBDs and large oncosomes are overlap-
ping in size [53,58,78,80], both can be stained posi-
tively by propidium iodide (most likely when the
vesicles become permeabilized) [40,42,58], and it is
currently undetermined whether large oncosomes can
expose a sufficient amount of PtdSer for A5 staining.
Thus, it could be difficult to distinguish ApoBDs from
Figure 4. ApoBDs undergo lysis over time. (a) Schematic of the release of intracellular proteins such as lactate dehydrogenase (LDH)
and fluorescent proteins GFP and mCherry from ApoBD undergoing membrane lysis. (b) Flow cytometry analysis of ApoBD enriched
samples, enriched by differential centrifugation, to determine ApoBD purity (n = 3). (c) ApoBD enriched samples were incubated for
0–6 h, and the level of ApoBD lysis determined by LDH release (n = 3). (d) Time-lapse images monitoring A5+ ApoBDs generated
from PANX1−/− GFP+ mCherry+ Jurkat T cells. Scale bar, 5 μm. Data are representative of at least three independent experiments. (e)
Loss of mCherry intensity in individual ApoBDs was quantified from microscopy images using the Zeiss Zen Lite 2.3 software and
normalized to first sign of ApoBD lysis (n = 15). Units shown are arbitrary and Δ change in mCherry signal was determined by
subtracting the mCherry signal at −150 min from the mCherry signal from all time points. (f) Monitoring ApoBD lysis by flow
cytometry based on the loss of GFP signal in ApoBDs. Left, flow cytometry plots of electronic gating strategy used for analysing
ApoBD lysis. Right, flow cytometry analysis of ApoBD lysis in UV-treated PANX1−/− GFP+ mCherry+ Jurkat T cells. Cells were
incubated for 4 to 24 h post UV treatment (n = 3). Error bars represent s.e.m.
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large oncosomes, especially if these EV subtypes were
isolated from tissue samples. However, since large
oncosomes are generated under non-apoptotic condi-
tions [78], large oncosomes are unlikely to contain
caspase-cleaved proteins like ApoBDs.
Although certain EV subtypes have overlapping size
range [1–6], size is a criterion often used to distinguish
different subtypes of EVs. As described above, it is impor-
tant to acknowledge the possibility that ApoBDs generated
from certain cell types could exist outside the traditional
range of 1–5 μm, as the size of ApoBDs could be dependent
on the size of the cell and the mechanism of apoptotic cell
disassembly. Thus, it may be difficult to clearly distinguish
larger ApoBDs from apoptotic cell bodies (a term used to
describe the remainder of an apoptotic cell that did not
undergo further fragmentation) and smaller ApoBDs from
other ApoEV subtypes. It should be noted that the study of
ApoBDs and other ApoEV subtypes is still in its infancy,
and we do not propose to broaden the size range for
ApoBDs but to recommend investigators to carefully eval-
uate in their experimental systems what should be consid-
ered as ApoBDs (e.g. based on the combination of
parameters/criteria as suggested in Table 1), rather than
making the assumption that ApoBDs are strictly 1–5 μm.
Whether further subdividing ApoBDs into large and small
ApoBDs could reveal biologically relevant information
remains to be defined.
In addition to PtdSer, cell type-specific markers are
also retained on the surface of ApoBDs [53,57], again not
surprising as ApoBDs appear to acquire a significant
portion of the plasma membrane [36,45]. However, it
should be noted that the levels of cell type-specific mar-
kers on ApoBDs are markedly lower compared to apop-
totic and viable cells, and should be monitored with
caution [53]. Furthermore, monitoring the presence of
caspase-cleaved proteins could be useful to help distin-
guish ApoBDs from large oncosomes. Identification of
caspase-cleaved proteins is simply a complementary
approach to indicate the presence of ApoEVs generated
from apoptotic cells in the sample. This further highlights
the importance to use multiple approaches and lines of
evidence to evaluate what ApoEV subtypes are present in
the sample, such as using methods that are suitable to
identify ApoEVs of interest, determining the size of
ApoEVs, and using ApoEV isolation procedure relevant
to a specific cell type.
It is well accepted that nuclear proteins and DNA
are found in ApoBDs [1–3], and certain nuclear
Figure 5. Formation of ApoEVs during apoptosis. ApoBDs and other ApoEV subtypes are generated during apoptosis. Although
PtdSer and cell-type specific markers can be found on ApoEVs, these ApoEVs display less PtdSer and cell-type specific marker
compared to apoptotic cells. Caspase-cleaved plasma membrane proteins (and cytoplasmic proteins, not depicted in the schematic)
can be found in ApoBDs. ApoBDs will undergo membrane lysis (i.e. become secondary necrotic) over time under in vitro conditions.
The progression of cell death and/or apoptotic cell disassembly should be monitored in ApoEV studies.
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proteins like histones as well as the presence of DNA
can be used as markers to validate the presence of
ApoBDs in a sample [24,38,81,82]. Although these
markers can be useful to distinguish ApoBDs from
other EV subtypes, it is becoming increasingly clear
that ApoBDs may not always contain nuclear materials
[53]. For example, ApoBDs generated from monocytes
via a beaded apoptopodia-dependent mechanism are
devoid of nuclear proteins (Figure 3(a–c)) and DNA
[45]. Furthermore, based on the live imaging data
available under both in vitro and in vivo conditions
[36,45,83] as well as evidence from flow cytometry and
electron microscopy-based analysis [33,53,84], cellular
contents are not distributed evenly into ApoBDs and it
is unlikely that all ApoBDs will contain a comparable
amount of nuclear contents. Thus, caution must be
taken when using nuclear materials as a marker for
ApoBDs.
Small EVs are thought to be relatively stable and
could maintain an intact phospholipid bilayer on the
surface [85,86], an important property for the transfer
intravesicle biomolecules to recipient cells to mediate
intercellular communication. Since ApoBDs have also
been proposed to mediate the trafficking of
microRNAs [82,87], oncogenes [88], cytokines [24],
autoantigens [38,89] and pathogen-derived antigens
[90], maintaining an intact membrane would be pre-
ferable. It should be noted that the stability of ApoBDs
is also an important parameter for any downstream
omics analysis as biomolecules like RNA, DNA and
proteins can be leaked out of lysed ApoBDs. Likewise,
lysis of ApoBDs may release damage-associated mole-
cular patterns (known as DAMPs), which could acti-
vate certain cell types, hence important for functional
studies downstream. Thus, determining whether
ApoBDs are intact and the kinetic of lysis as shown
in this study is another property of ApoBDs that
should be considered in future studies. Although the
methods used in this study to monitor ApoBD lysis
may not be suitable to determine the percentage of
ApoBD that are intact or lysed for all types of samples
(e.g. ApoBDs isolated from primary cells or tissues), it
is possible to stain ApoBDs with propidium iodide to
monitor vesicle lysis [40]. However, caution must be
taken with this approach as this method relies on
sufficient amount of DNA and/or RNA retained in
lysed ApoBDs.
ApoEVs, in particular ApoBDs, are one the first type
of EVs being observed in tissue samples [33]. The
formation of ApoBDs is not a rare event in vitro or
in vivo [24,33,36,40,45,83], and the highly organized
step-wise progression of ApoBD formation can be
readily observed live in cultured cells using standard
laboratory microscopes [34]. Nevertheless, ApoBDs are
arguably the least characterized EV subtype, possibly
due to the notion that they are simply “debris” gener-
ated from dying cells and cellular contents are distrib-
uted into these vesicles randomly. We hope that the
discussion and findings in this study have clarified and
extended our understanding of ApoBDs, and encou-
rage investigators to use a combination of parameters/
criteria for the characterization of ApoBD in future
studies.
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